MRK – Merck & Co., Inc.
Float Short %
1.11
Margin Of Safety %
12
Put/Call OI Ratio
0.61
EPS Next Q Diff
-0.93
EPS Last/This Y
1.32
EPS This/Next Y
-0.17
Price
99.72
Target Price
106.29
Analyst Recom
2.04
Performance Q
18.59
Relative Volume
1.25
Beta
0.31
Ticker: MRK
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-11-10 | MRK | 86.74 | 0.66 | 0.58 | 678250 |
| 2025-11-11 | MRK | 90.95 | 0.66 | 0.19 | 681243 |
| 2025-11-12 | MRK | 91.49 | 0.61 | 0.20 | 723181 |
| 2025-11-13 | MRK | 93 | 0.60 | 0.18 | 750328 |
| 2025-11-14 | MRK | 92.96 | 0.62 | 0.20 | 747668 |
| 2025-11-17 | MRK | 92.88 | 0.63 | 0.48 | 722881 |
| 2025-11-18 | MRK | 96.61 | 0.63 | 0.31 | 729829 |
| 2025-11-19 | MRK | 95.09 | 0.62 | 0.66 | 743983 |
| 2025-11-20 | MRK | 94.97 | 0.63 | 1.33 | 752759 |
| 2025-11-21 | MRK | 97.79 | 0.62 | 0.24 | 754676 |
| 2025-11-24 | MRK | 100.41 | 0.61 | 0.15 | 666468 |
| 2025-11-25 | MRK | 105.65 | 0.54 | 0.65 | 745673 |
| 2025-11-26 | MRK | 104.68 | 0.56 | 0.43 | 763610 |
| 2025-12-01 | MRK | 101.85 | 0.58 | 1.14 | 724877 |
| 2025-12-02 | MRK | 101.06 | 0.59 | 0.78 | 739755 |
| 2025-12-03 | MRK | 102.32 | 0.60 | 0.57 | 748445 |
| 2025-12-04 | MRK | 100.89 | 0.61 | 0.75 | 754082 |
| 2025-12-05 | MRK | 99.72 | 0.61 | 0.55 | 760107 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-11-10 | MRK | 86.75 | 18.4 | 5660.6 | 8.96 |
| 2025-11-11 | MRK | 90.95 | 18.4 | 6770.6 | 8.96 |
| 2025-11-12 | MRK | 91.46 | 19.2 | 5665.6 | 8.97 |
| 2025-11-13 | MRK | 92.94 | 19.2 | 5219.3 | 8.97 |
| 2025-11-14 | MRK | 92.95 | 19.1 | 4812.5 | 8.97 |
| 2025-11-17 | MRK | 92.84 | 19.1 | 4785.0 | 8.97 |
| 2025-11-18 | MRK | 96.46 | 19.1 | 5791.1 | 8.97 |
| 2025-11-19 | MRK | 95.05 | 19.1 | 4444.2 | 8.97 |
| 2025-11-20 | MRK | 94.96 | 19.1 | 4782.8 | 8.96 |
| 2025-11-21 | MRK | 97.76 | 19.2 | 5553.3 | 8.97 |
| 2025-11-24 | MRK | 100.41 | 19.2 | 5725.8 | 8.97 |
| 2025-11-25 | MRK | 105.66 | 19.3 | 6378.0 | 8.97 |
| 2025-11-26 | MRK | 104.64 | 19.3 | 4781.7 | 8.97 |
| 2025-12-01 | MRK | 101.84 | 18.9 | 4293.5 | 8.97 |
| 2025-12-02 | MRK | 101.03 | 18.9 | 4827.7 | 8.97 |
| 2025-12-03 | MRK | 102.27 | 18.9 | 5346.2 | 8.97 |
| 2025-12-04 | MRK | 100.89 | 18.9 | 4683.4 | 8.97 |
| 2025-12-05 | MRK | 99.72 | 18.9 | 4731.4 | 8.97 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-11-10 | MRK | -0.31 | -0.70 | 1.08 |
| 2025-11-11 | MRK | -0.31 | -0.70 | 1.08 |
| 2025-11-12 | MRK | -0.57 | -0.70 | 1.04 |
| 2025-11-13 | MRK | -0.57 | -0.70 | 1.04 |
| 2025-11-14 | MRK | -0.57 | -0.70 | 1.04 |
| 2025-11-17 | MRK | -0.57 | 0.10 | 1.04 |
| 2025-11-18 | MRK | -0.57 | 0.10 | 1.04 |
| 2025-11-19 | MRK | -0.57 | 0.10 | 1.04 |
| 2025-11-20 | MRK | -0.57 | 0.10 | 1.04 |
| 2025-11-21 | MRK | -0.57 | 0.10 | 1.04 |
| 2025-11-24 | MRK | -0.52 | -1.21 | 1.04 |
| 2025-11-25 | MRK | -0.63 | -1.21 | 1.04 |
| 2025-11-26 | MRK | -0.63 | -1.21 | 1.11 |
| 2025-12-01 | MRK | -0.63 | -1.29 | 1.11 |
| 2025-12-02 | MRK | -0.63 | -1.29 | 1.11 |
| 2025-12-03 | MRK | -0.63 | -1.29 | 1.11 |
| 2025-12-04 | MRK | -0.63 | -1.29 | 1.11 |
| 2025-12-05 | MRK | -0.63 | -1.29 | 1.11 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.58
Avg. EPS Est. Current Quarter
2.05
Avg. EPS Est. Next Quarter
1.65
Insider Transactions
-0.63
Institutional Transactions
-1.29
Beta
0.31
Average Sales Estimate Current Quarter
16182
Average Sales Estimate Next Quarter
16004
Fair Value
111.92
Quality Score
97
Growth Score
80
Sentiment Score
77
Actual DrawDown %
25.9
Max Drawdown 5-Year %
-43.4
Target Price
106.29
P/E
13.19
Forward P/E
11.31
PEG
1.3
P/S
3.87
P/B
4.78
P/Free Cash Flow
18.97
EPS
7.56
Average EPS Est. Cur. Y
8.97
EPS Next Y. (Est.)
8.8
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
29.79
Relative Volume
1.25
Return on Equity vs Sector %
9.8
Return on Equity vs Industry %
0.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.02
EBIT Estimation
4731.4
Merck & Company, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading